Certara, a biosimulation company, reported that the Simcyp group has been awarded two new grants from the U.S. FDA to expand its predictive models for assessing drug virtual bioequivalence (VBE) and to create a formulation toolbox for topically applied drugs. These capabilities aim to enable safer, faster, and more cost-effective product development of both complex generics and novel drugs. Bioequivalence (BE) studies, which are used to show that the rate and extent of absorption of the inves...